Literature DB >> 24096163

Explaining the inconsistent associations of PR interval with mortality: the role of P-duration contribution to the length of PR interval.

Elsayed Z Soliman1, Michael Cammarata2, Yabing Li3.   

Abstract

BACKGROUND: There is a strong interest in PR interval as a predictor for adverse outcomes. However, inconsistent reports have emerged.
OBJECTIVE: The purpose of this study was to test the hypothesis that the significance of PR interval as a predictor depends on the level of contribution of P duration to its length, a contribution that varies across populations.
METHODS: We tested our hypothesis in 7501 participants from the Third National Health and Nutrition Examination Survey (NHANES III). Participants were divided into two subgroups based on the median P-duration contribution to PR interval (P duration/PR interval * 100). The risk of mortality associated with prolonged (>200 ms) and short (<120 ms) PR interval compared with normal PR interval was examined in all participants and each subgroup.
RESULTS: P-duration contribution to the length of PR interval ranged from 30% to 90% (median 70%). During median follow-up of 13.8 years, 2541 deaths occurred. In a multivariable adjusted model, short but not prolonged PR interval was associated with mortality (hazard ratio [HR], (95% confidence interval [CI]): 1.54 (1.18, 2.00) and 1.02 (0.90, 1.16), respectively). However, in a stratified analysis by P-duration contribution to PR interval, both short and prolonged PR interval were associated with mortality in participants with high P-duration contribution (HR (95% CI):1.46 (1.10, 1.94) and 2.00 (1.34, 2.99), respectively) but not in participants with low P-duration contribution (HR (95% CI):1.53 (0.68, 3.41) and 0.99 (0.87, 1.13), respectively); interaction P = .008.
CONCLUSION: PR-interval associations with outcomes are dictated by the level of contribution of P duration to its length, a contribution that has a wide range and is expected to vary across populations. These findings could explain the inconsistent reports of PR-interval associations in different studies and call for caution when using PR interval in risk prediction models.
© 2013 Heart Rhythm Society Published by Heart Rhythm Society All rights reserved.

Entities:  

Keywords:  AF; AV; BMI; CI; ECG; HR; P duration; P duration/PR interval ratio; P-wave indices; P/PR; PR segment; PR-interval; SD; atrial fibrillation; atrioventricular; body mass index; confidence interval; electrocardiogram; hazard ratio; standard deviation

Mesh:

Year:  2013        PMID: 24096163     DOI: 10.1016/j.hrthm.2013.10.003

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  15 in total

1.  Inter-relationship between electrocardiographic left ventricular hypertrophy and QT prolongation as predictors of increased risk of mortality in the general population.

Authors:  Elsayed Z Soliman; Amit J Shah; Andrew Boerkircher; Yabing Li; Pentti M Rautaharju
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-04-24

2.  Subclinical myocardial injury identified by cardiac infarction/injury score and the risk of mortality in men and women free of cardiovascular disease.

Authors:  Wesley T O'Neal; Amit J Shah; Jimmy T Efird; Pentti M Rautaharju; Elsayed Z Soliman
Journal:  Am J Cardiol       Date:  2014-07-17       Impact factor: 2.778

Review 3.  Characteristics of PR interval as predictor for atrial fibrillation: association with biomarkers and outcomes.

Authors:  Katja Schumacher; Nikolaos Dagres; Gerhard Hindricks; Daniela Husser; Andreas Bollmann; Jelena Kornej
Journal:  Clin Res Cardiol       Date:  2017-04-05       Impact factor: 5.460

Review 4.  Atrial Fibrillation Predictors: Importance of the Electrocardiogram.

Authors:  David M German; Muammar M Kabir; Thomas A Dewland; Charles A Henrikson; Larisa G Tereshchenko
Journal:  Ann Noninvasive Electrocardiol       Date:  2015-11-02       Impact factor: 1.468

5.  Electrocardiographic deep terminal negativity of the P wave in V1 and risk of mortality: the National Health and Nutrition Examination Survey III.

Authors:  Larisa G Tereshchenko; Amit J Shah; Yabing Li; Elsayed Z Soliman
Journal:  J Cardiovasc Electrophysiol       Date:  2014-06-11

6.  Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes.

Authors:  Jonathan D Mosley; M Benjamin Shoemaker; Quinn S Wells; Dawood Darbar; Christian M Shaffer; Todd L Edwards; Lisa Bastarache; Catherine A McCarty; Will Thompson; Christopher G Chute; Gail P Jarvik; David R Crosslin; Eric B Larson; Iftikhar J Kullo; Jennifer A Pacheco; Peggy L Peissig; Murray H Brilliant; James G Linneman; John S Witte; Josh C Denny; Dan M Roden
Journal:  Circ Cardiovasc Genet       Date:  2017-04

7.  PR-Interval Components and Atrial Fibrillation Risk (from the Atherosclerosis Risk in Communities Study).

Authors:  Justin W Smith; Wesley T O'Neal; M Benjamin Shoemaker; Lin Y Chen; Alvaro Alonso; S Patrick Whalen; Elsayed Z Soliman
Journal:  Am J Cardiol       Date:  2016-11-01       Impact factor: 2.778

8.  Association between sleep disordered breathing and electrocardiographic markers of atrial abnormalities: the MESA study.

Authors:  Younghoon Kwon; Jeffrey R Misialek; Daniel Duprez; Alvaro Alonso; David R Jacobs; Susan R Heckbert; Susan Redline; Elsayed Z Soliman
Journal:  Europace       Date:  2017-11-01       Impact factor: 5.214

9.  Smoking Accelerates Atrioventricular Conduction in Humans Concordant with Increased Dopamine Release.

Authors:  Affan B Irfan; Claudia Arab; Andrew P DeFilippis; Pawel Lorkiewicz; Rachel J Keith; Zhengzhi Xie; Aruni Bhatnagar; Alex P Carll
Journal:  Cardiovasc Toxicol       Date:  2020-10-12       Impact factor: 3.231

10.  The Association between the PR Interval and Left Ventricular Measurements in the Multiethnic Study of Atherosclerosis.

Authors:  Michael P Husby; Elsayed Z Soliman; Jeffrey J Goldberger; Kiang Liu; Don Lloyd-Jones; Ramon Durazo-Arvizu; Holly Kramer
Journal:  Cardiol Res Pract       Date:  2015-10-19       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.